domingo, 27 de septiembre de 2026
BuscarExplore
es.VIA.NEWS
Via News Knowledge File

Merck & Co., Inc.

organization80% conf.·synced Sep 27, 2026

Pharmaceutical company based in Rahway, NJ, known as MSD outside US and Canada

60
sourced metrics
660
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
156.45USD
Sep 10, 2026reference only
Stock Return Ytd
35.9%
Sep 10, 2026reference only
Price 52 Week Low
77.60USD
Sep 10, 2026reference only
Market Cap
357024407735USD
Sep 10, 2026reference only
Stock Price
144.71USD
Sep 10, 2026reference only
Shares Outstanding
2467171638.0shares
Jul 31, 2026reference only
Cost Of Revenue
4395000000.0USD
Jun 30, 2026reference only
Cash
6849000000.0USD
Jun 30, 2026reference only
Eps
-0.54USD_per_share
Jun 30, 2026reference only
Revenue
16607000000.0USD
Jun 30, 2026reference only
Rd Expense
9741000000.0USD
Jun 30, 2026reference only
Total Assets
129802000000.0USD
Jun 30, 2026reference only
Stockholders Equity
41933000000.0USD
Jun 30, 2026reference only
Net Income
-1335000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
3918000000.0USD
Mar 31, 2026reference only
Capex
991000000.0USD
Mar 31, 2026reference only

Stated objectives

Enroll approximately 675 patients in KANDLELIT-007 Phase 3 trial

source
target: 675 patients stated

Evaluate progression-free survival as primary endpoint in PD-L1 TPS ≥1% patients in KANDLELIT-007

source
stated

Evaluate secondary endpoints including PFS in all patients, overall survival, objective response rate, duration of response, and safety in KANDLELIT-007

source
stated

Submit regulatory filings worldwide for KEYTRUDA + Padcev combination in muscle-invasive bladder cancer based on KEYNOTE-B15/EV-304 results

source
stated

Initiate second Merck-sponsored pivotal trial of zanzalintinib and belzutifan in RCC

source
stated

Full-year sales forecast

source
target: $64.5 billion to $65 billion by 2025-12-31 00:00:00stated

Full-year EPS forecast

source
target: $8.93 to $8.98 by 2025-12-31 00:00:00stated

Improving outcomes and addressing significant unmet needs for patients with hematologic neoplasms and malignancies

source
stated

Become the premier research-intensive biopharmaceutical company in the world

source
stated

Deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals

source
stated

Relationship graph · 660 connections

Developed by
267
Competes with
67
Employs
46
acquired by
42
Partnered with
41
Covered by
28
regulates
28
headquartered in
27
headquartered in
Rahway, New Jersey
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com